Мычка В. Б. Преимущества бета-адреноблокаторов с вазодилатирующими свойствами для лечения артериальной гипертонии. Кардиоваскулярная терапия и профилактика. 2012;11(3):87-92.
1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 1979; 59: 8-13.
2. Haffner S, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
3. Pickup JC, Crook MA. Is Type II diabetes mellitus a disease of innate immune system? Diabetologia. 1998; 41: 1241-8.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-13.
5. Jonas M, Reicher-Reiss H, Royko V, et al. Usefullness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996; 77: 1273-7.
6. ISIS-1. First International Study of Infarct survival Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet 1986; 2: 57-66.
7. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J 1985; 6: 199-226.
8. Hjalmarson A, Esmefeldt D, Helritz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double blind randomized trial. Lancet 1981; 2: 823-7.
9. Cleophas Ton J. Experimental evidence of selective antagonistic action of Nebivolol on β1-adrenergic receptors. J Clin Med 1998; II: 1-8.
10. Van Nueten JM, Schuurkes JA, Van den Brink HW, et al. In vitro pharmacological profile of R065824, a potent and selective β1-adrenergic antagonist. JRF Preclinical Research Report R065834/8. November 1985.
11. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patient with heart failure( SENIORS). Eur Heart J 2005; 26: 215-25.
12. Cockroft JR, Chowenczyk PHJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence of L-arginine/NO-dependent mechanism. J Pharmacol Experim Therap 1995; 274: 1067-71.
13. Van De Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of Nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. J Cardiovasc Pharm 1988; 11: 552-63.
14. Janssens WJ, Geyskens D, Proost F. Comparison of the β-adrenergic antagonistic effects of Nebivolol, carvedilol, celiprolol and bisoprolol on isolated right atria and trachea of the guinea-pig. Preclinical Research Report. June 1996.
15. De Cree J, Geukens H, Verhaegen H, et al. Double blind placebo-controlled cross-over study evaluating the acute haemodynamic effects of dl-Nebivolol 5 mg, d-Nebivolol 2,5 mg an l-Nebivolol 2,5 mg in healthy volunteers. JRF Clinical Research Report on R67555 NO-35. February 1989.
16. Blankestijn P.J, Van Den Meiracker AH, Man In’t Veld AJ, et al. Nebivolol. An acute and long term study in essential hypertension. Drug Invest 1991; 3 (Suppl.1): 152-4.
17. Jennings G, Esler M, Dart A, et al. Effects of Nebivolol on haemodynamics, cardiac dimensions and function, cardiovascular reflexes and biochemical measures of sympathetic activity in normal human subjects. Drug Invest. 1991; 3 (suppl.1): 51-9.
18. Louis WJ, McNeil JJ, Drummer OH, et al. A study to establish the acute effects of Nebivolol on blood pressure and whether or not there are first dose postural effects in middle aged and elderly patients. Unpublished report on NEB-AUS-3, March 1995.
19. Kleiger RE, Miller JP, Bigger JT, Moss AJ and the Multicenter Post-Infarction Reseach GrouP. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-62.
20. Zanchetti A. Trough: peak ratio of the blood pressure response to dihydropiridine calcium antagonists. J Hypertens 1994; 12(8): S97-106.
21. Van Nueten L, Lacourcióre Y, Vyssoulis G, et al. Nebivolol versus nifedipine in treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Therapeutics 1998; 5: 237-43.
22. Chazova IE, Mychka VB Metabolic syndrome. M.: Media Medica 2008; p. 324. Russian (Чазова И.Е., Мычка В.Б. Метаболический синдром. – М.: Медиа Медика 2008; 324 с).
23. Mychka VB, Zhernakova JV, Zjuzina NE. The effectiveness of nebivolol in patients with diabetes mellitus and metabolic syndrome. CONSILIUM MEDICUM 2008; 10(5):86-90. Russian (Мычка В.Б., Жернакова Ю.В., Зюзина Н.Е. и др. Эффективность небиволола у больных сахарным диабетом и метаболическим синдромом. CONSILIUM MEDICUM 2008, том 10 №5, 86-90).
24. Сheremushkin SV, Kucherjavyj JA, Oganesjan TS. The effectiveness and safety of two regimens of combined hypotensive therapy in patients with mild and moderate hypertension. Russ J Cardiol 2011; 3(89): 40-5. Russian Черемушкин С.В., Кучерявый Ю.А., Оганесян Т.С. Эффективность и безопасность двух режимов комбинированной гипотензивной терапии у больных с мягкой и умеренной формой артериальной гипертензии. Российский кардиологический журнал 2011; 3 (89): 40-5.
25. Dowicin VL. Sudden cardiac death. Clinical medicine 1992; 9-10:30-4. Russian (Дощицин В.Л. Внезапная аритмическая смерть. Клин мед 1992; 9-10; 30-4).
26. Ptosing P, Breum L, Major-Peder sen A, et al. Prolonged QTc interval predicts mortality in patients with I type dibets mellitus. Dibetic Med 2001; 18: 199-205.
27. Shishova TA, Mychka VB, Laptev DN. The influence of nebivolol on the BP level, QT interval duration and HRV indicators in patients with mild hypertension and metabolic syndrome during bifunctional ECG and BP monitoring. Vestnik aritmologii 2009. Supplement A, p.41. Russian (Шишова Т.А., Мычка В. Б., Лаптев Д.Н. и др. Влияние небиволола на уровень АД, длительность интервала QT и показатели ВРС у больных с мягкой артериальной гипертонией и метаболическим синдромом при бифункциональном мониторироварии ЭКГ и АД. Вест аритмол 2009; Приложение А: 41).
28. Bertel O, Marx B, Conen D. Effects of antihypertensive treatment on cerebral perfusion. Am J Med 1987; 82-92.
29. Meyer JS, Rogers RL, Mortel RF. Prospective analysis of long-term control of mild hypertension in cerebral blood flow. Stroke 1985; 16(6): 985-90.
30. Hares P, James IM, Griffith D. Effect of acebutolol on cerebral circulation of a man. Br J Clin Pharmacol 1977; 4: 373-5.
